1 Ilic D, Neuberger MM, Djulbegovic M, Dahm P. Screening for prostate cancer. Cochrane Database Syst Rev. 2013;2013(1):CD004720.
2 Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al.; ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009 26;360(13):1320-8.
3 European Associaton of Urology [Internet]. Mottet N, Cornford P, van der Bergh RCN, Briers E, Expert Patient Advocate (European Prostat Cancer Coaliton/Europa UOMO), Eberli D, et al. EAU – EANM – ESTRO – ESUR – ISUP – SIOG Guidelines on Prostate Cancer. EAU Guidelines Office, Arnhem, The Netherlands. c2023 [cited 2022 Nov 01]. Available
https://uroweb.org/guidelines/prostate-cancer/chapter/diagnostic-evaluation
5 Ström P, Nordström T, Aly M, Egevad L, Grönberg H, Eklund M. The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential. Eur Urol. 2018;74(2):204–10.
6 Edwards SM, Kote-Jarai Z, Meitz J, Hamoudi R, Hope Q, Osin P, et al.; Cancer Research UK/Bristish Prostate Group UK Familial Prostate Cancer Study Collaborators; British Association of Urological Surgeons Section of Oncology. Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet. 2003;72(1):1–12.
7 Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, et al. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N Engl J Med. 2016;375(5):443–53.
8 Na R, Zheng SL, Han M, Yu H, Jiang D, Shah S, et al. Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death. Eur Urol. 2017;71(5):740–7.
9 Mark JR, McDougall C, Giri VN. Genetic Testing Guidelines and Education of Health Care Providers Involved in Prostate Cancer Care. Urol Clin North Am. 2021;48(3):311–22.
11 Duffy, Michael J. Biomarkers for prostate cancer: prostate-specific antigen and beyond. Clinical Chemistry and Laboratory Medicine (CCLM). 2020;58(3):326–39.
12 Hatzinger M, Hubmann R, Moll F, Sohn M. Die Geschichte der Prostatektomie - Von den Anfängen bis DaVinci [The history of prostate cancer from the beginning to DaVinci]. Aktuelle Urol. 2012;43(4):228–30. German.
13 Ilic D, Evans SM, Allan CA, Jung JH, Murphy D, Frydenberg M. Laparoscopic and robotic-assisted versus open radical prostatectomy for the treatment of localised prostate cancer. Cochrane Database Syst Rev. 2017;9(9):CD009625.
14 Fantus RJ, Cohen A, Riedinger CB, Kuchta K, Wang CH, Yao K, Park S. Facility-level analysis of robot utilization across disciplines in the National Cancer Database. J Robot Surg. 2019;13:293–9.
15 Lai A, Dobbs RW, Talamini S, Halgrimson WR, Wilson JO, Vigneswaran HT, Crivellaro S. Single port robotic radical prostatectomy: a systematic review. Transl Androl Urol. 2020;9(2):898–905.
16 Reddy D, Peters M, Shah TT, van Son M, Tanaka MB, Huber PM, et al. Cancer Control Outcomes Following Focal Therapy Using High-intensity Focused Ultrasound in 1379 Men with Nonmetastatic Prostate Cancer: A Multi-institute 15-year Experience. Eur Urol. 2022;81(4):407–13.
17 Pellegrino A, Cirulli GO, Mazzone E, Barletta F, Scuderi S, de Angelis M, et al. Focal therapy for prostate cancer: what is really needed to move from investigational to valid therapeutic alternative? A narrative review. Ann Transl Med. 2022;10(13):755.